Transactions
1
Insider / Lyell Immunopharma, Inc.
Innovative Cellular Therapeutics Holdings Ltd
Insider at Lyell Immunopharma, Inc.
- Company
- Lyell Immunopharma, Inc.
- Ticker
- LYEL
- First filing on record
- July 27, 2026
- Latest trade on record
- July 27, 2026
- SEC filings
- EDGAR ↗
Innovative Cellular Therapeutics Holdings Ltd, Insider at Lyell Immunopharma, Inc., has disclosed 1 transaction in LYEL since July 27, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed July 27, 2026, 0 days after the trade.
Open-market buys
0
Sales
0
Avg. disclosure lag
0.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Innovative Cellular Therapeutics Holdings Ltd reported 1 transaction that was neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| J | Other acquisition or disposal | 1 | 44,000 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 1 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| LYEL | Other J | July 27, 2026 | July 27, 2026 | 0d | 44,000 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| July 27, 2026 | Form 4 | 0001140361-26-029817 | 1 | published | EDGAR ↗ |
Other insiders at Lyell Immunopharma, Inc.
- GLAXOSMITHKLINE PLC Insider 33 rows
- Aguirre Jarrad Mattieu Chief Medical Officer 2 rows
- Hill Stephen J. Chief Operating Officer 2 rows
- Lee Gary K. Chief Scientific Officer 2 rows
- Seely Lynn President and CEO 2 rows
- Bulis Veronica Sanchez VP, Corporate Controller 1 row
- Shook David Chief Medical Officer 1 row
Everyone on file, with contracts and lobbying under the company's name: Lyell Immunopharma, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 1 | July 27, 2026 | July 27, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.